Strategic partnerships Leverage Serpin Pharma’s active collaboration track record with industry players like Estée Lauder and Dogwood Therapeutics to target partnerships in anti-inflammatory skincare, cosmetic ingredients, and oncology supportive care spaces.

Clinical pipeline Focus on SP16 and SP163M opportunities for cancer-related pain and chemotherapy-induced peripheral neuropathy, presenting a clear path to co-development, licensing, or milestone-driven collaborations with pharma and biotech companies.

Funding signals Target potential co-funding or grant-backed programs given the company’s experience securing an NCI grant and its ongoing clinical-stage status to de-risk joint R&D ventures and accelerate clinical milestones.

Cosmetic applications Explore cosmetic and skincare partnerships with Estée Lauder to commercialize anti-inflammatory research into longevity and skin health ingredients, opening a high-margin consumer health segment.

Small team agility Position Serpin Pharma as a nimble partner for quick-start collaborations with mid-market and specialty pharma, offering accelerated decision timelines and lean development programs suitable for smaller sales cycles.